



MEDICAL THERAPIES AND PHARMACOLOGY

## DESMODIUM ADSCENDENS AND LITHOTAMNIUM CALCAREUM IN THE MANAGEMENT OF THE PRO-INFLAMMATORY CONDITION IN PATIENTS WITH HEAD AND NECK CANCERS RECEIVING CHEMOTHERAPY. DESMOVIT® STUDY

*Luca Imperatori<sup>(1)</sup> - Damiano Giardini<sup>(2)</sup> - Gino Latini<sup>(2)</sup> - Giuseppe Migliori<sup>(2)</sup> - Claudio Blasi<sup>(3)</sup> - Feisal Bunkheila<sup>(3)</sup> - Cesare Breschi<sup>(4)</sup> - Rodolfo Mattioli<sup>(1)</sup> - Ezio Abbiati<sup>(5)</sup>*

*Az. Ospedaliera Ospedali Riuniti Marche Nord, Uoc Medical Oncology, Fano, Italy<sup>(1)</sup> - Az. Ospedaliera Ospedali Riuniti Marche Nord, Uoc Otorhinolaryngology, Fano, Italy<sup>(2)</sup> - Az. Ospedaliera Ospedali Riuniti Marche Nord, Uoc Radiotherapy, Fano, Italy<sup>(3)</sup> - Az. Ospedaliera Ospedali Riuniti Marche Nord, Uoc Anaesthesia E Resuscitation, Fano, Italy<sup>(4)</sup> - Phytoitalia, R&d, Corbetta (mi), Italy<sup>(5)</sup>*

**Introduction:** Head and neck cancers show some care and pathophysiological complexities due to the metabolic and pro inflammatory abnormalities associated with the disease.

**Ipothesis:** investigate the potential benefit in the supportive therapy for the treatment of 2nd or 3rd line of patients with head and neck neoplasm, by concomitant administration of a food supplement containing Desmodium Adscendens, an anti-allergic, antioxidant, hepatoprotective plant and Lithotamnium Calcareum, calcified seaweed containing carbonate salts, trace elements, alginates, vitamin C with remineralization activity and favors the acid-base balance of the organism.

**Methods:** From January 2013 to August 2017, 12 patients with H&N cancer receiving II° or III° line chemotherapy treatment, were included into the Desmovit Study. Patients received Desmodium adscendens totum leaf 300mg, Lithotamnium calcareum totum whole seaweed 50 mg, at a dose of 3 capsule a day, 15 minutes before main meals.

**Results/Conclusion:** Analysis of evolution of PCR, monitored in patients treated with integrated therapy, in some cases has shown a decreasing initial trend, especially during the first weeks of treatment, then remained stable in most patients. No toxicity G3-G4 were observed, related to the concomitant chemotherapy anticancer treatment, or other adverse events. According to ECOG performance status requirements, monitoring of PS, BMI and body weight showed a substantial stability trend. Patients on study showed a stability trend of the Albuminemia concentration.





Declaration of conflict of interest: The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

